Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.59 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.52 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.48 |
| ▸ | GSK3B | P49841 | 1/20 | 0.48 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.48 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | GRM5 | P41594 | 4/20 | 0.47 |
| ▸ | CDC7 | O00311 | 1/20 | 0.47 |
| ▸ | CDK2 | P24941 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | XDH | P47989 | 1/20 | 0.46 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.45 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.45 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.45 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.45 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.45 |
| ▸ | SYK | P43405 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29432635 | 0.82 | DYRK1A (0.54) | MAP4K4DYRK1AGSK3BCDC7CDK2 | |
| SCHEMBL3397985 | 0.82 | DYRK1A (0.54) | MAP4K4DYRK1AGSK3BCDC7CDK2 | |
| SCHEMBL9792841 | 0.81 | CLK4 (0.61) | CLK4MAP4K4MAOBGRM5GABRA1 | |
| SCHEMBL14072794 | 0.79 | CLK4 (0.59) | CLK4DYRK1AMAOBGRM5ALDH1A1 | |
| SCHEMBL5562895 | 0.79 | CLK4 (0.59) | CLK4MAP4K4MAOBGRM5ALDH1A1 | |
| SCHEMBL23809618 | 0.79 | DYRK1A (0.45) | CLK4DYRK1AGSK3BGRM5CDC7 | |
| SCHEMBL29620507 | 0.79 | CLK4 (0.59) | CLK4MAP4K4ADORA2AADORA1MAOB | |
| SCHEMBL23228524 | 0.79 | CLK4 (0.59) | CLK4MAP4K4ADORA2AADORA1MAOB | |
| SCHEMBL312451 | 0.79 | — | — | |
| SCHEMBL31294130 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11370784-B2 | Cyano-substituted heterocycles with activity as inhibitors of USP30 | MISSION THERAPEUTICS LIMITED (GB) | 2022-06-28 | — | — | US | disclosed |
| US-20210284631-A1 | CYANO-SUBSTITUTED HETEROCYCLES WITH ACTIVITY AS INHIBITORS OF USP30 | MISSION THERAPEUTICS LIMITED (GB) | 2021-09-16 | — | — | US | disclosed |
| EP-3523291-B1 | CYANO-SUBSTITUTED HETEROCYCLES WITH ACTIVITY AS INHIBITORS OF USP30 | MISSION THERAPEUTICS LTD (GB) | 2021-04-14 | — | — | EP | disclosed |
| US-10316049-B2 | Tank-binding kinase inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2019-06-11 | — | — | US | disclosed |
| WO-2017106556-A1 | TANK-BINDING KINASE INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2017-06-22 | — | — | WO | disclosed |
| US-20170174713-A1 | TANK-BINDING KINASE INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. | 2017-06-22 | — | — | US | disclosed |
| US-20170174713-A1 | TANK-BINDING KINASE INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. | 2017-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210284631-A1 | CYANO-SUBSTITUTED HETEROCYCLES WITH ACTIVITY AS INHIBITORS OF USP30 | USP30, USP28, USP1 | CLK4 2870/4885MAP4K4 3079/4885DYRK1A 4041/4885 |
| US-11370784-B2 | Cyano-substituted heterocycles with activity as inhibitors of USP30 | USP30, USP28, USP1 | CLK4 2870/4885MAP4K4 3079/4885DYRK1A 4041/4885 |
| US-20170174713-A1 | TANK-BINDING KINASE INHIBITOR COMPOUNDS | TBKBP1, TNKS1BP1, TNKS | CLK4 1343/4885MAP4K4 311/4885DYRK1A 2043/4885 |
| US-10316049-B2 | Tank-binding kinase inhibitor compounds | TBKBP1, TNKS1BP1, TNKS | CLK4 1343/4885MAP4K4 311/4885DYRK1A 2043/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.